ObsEva SA to Attend BioEquity Europe 2017 in Paris
May 16, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - 16 May 2017 -...
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017
May 11, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids
April 25, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - PRIMROSE 1 and PRIMROSE 2, pivotal...
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC
March 24, 2017 12:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - 24 March 2017 -...
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
March 17, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - OBE022 is ObsEva's potential...
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
March 07, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - IMPLANT2 study to confirm efficacy and...
ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC
February 03, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - February 03,...
ObsEva SA Announces Pricing of Initial Public Offering
January 25, 2017 22:56 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland - January 25, 2017 -...
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
January 17, 2017 05:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 17 January 2017 -...
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
January 13, 2017 07:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - First-in-class orally active...